• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Jan. 8, 2018

View Archived Issues

Money raised by biotech: Jan. 1 – Dec. 31, 2017

Read More

Biotech money raised by month in 2017

Read More

Public financing of biotechnology companies: Commenced trading in December 2017

Read More

Public financing of biotechnology companies: Filed and pending IPOs in December 2017

Read More

Other financings of public biotechnology companies in December 2017

Read More

Venture capital and other investments in private biotech companies in December 2017

Read More

Milestone payments from corporate partners in December 2017

Read More

The week's biggest gainers and losers

Read More

BioWorld stock report for public biotechnology companies

Read More

BioWorld Stock Index 2017

Read More

Nasdaq Stock Index 2017

Read More

Above average performance for biopharma

The biopharmaceutical industry's annual report card posted a B-plus. The BioWorld Biopharmaceutical Index, which embraces 21 of the top blue chip companies, generated a healthy 9 percent jump in value and the BioWorld Drug Developers Index soared a spectacular 55 percent in 2017. In a normal year, those returns would be more than enough to earn an A rating. However, the sector stumbled in the second half of the year with the Biopharmaceutical Index recording a 15 percent jump in value for the first six months of 2017, but a disappointing 5 percent drop in value in the second half of the year. Read More

'Spirit' of JPM lives on as other meetings muscle in on biopharma playground

Two weeks before the start of the 36th annual J.P. Morgan (JPM) Healthcare Conference, the annual gauge of life sciences investor sentiment, organizers caused a firestorm with their decision to bar media from the breakout sessions that follow canned presentations by 480 public and private companies over the four-day meeting. They relented 24 hours later, after media outlets took to Twitter to complain and stories in consumer press riled up retail investors, who publicly charged the forum with giving preferential treatment to institutional customers. Read More

FDA approvals hit records in 2017: most ever NMEs, orphan drugs, biosimilar

If ever a statement was made, it was made in 2017 by the FDA with a record number of approvals that dwarfed last year's numbers in every aspect. The most dramatic change was seen through a doubling of the new molecular entities (NMEs) approved, as well as a 37 percent increase in orphan drug approvals. BioWorld reported on the approval of 46 NMEs, in contrast with 2016's 22 NMEs approved. (See BioWorld Insight, Jan. 2, 2017.) Read More

Week in review

Read More

Word on the street

Read More

Week in Washington

Read More

Correction

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 11, 2025.
  • Red and blue bispecific antibodies

    3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race

    BioWorld
    3Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert...
  • Neuronata-R

    Corestemchemon preps US BLA filing for stem cell ALS therapy

    BioWorld Asia
    Corestemchemon Inc. is planning to file a BLA for Neuronata-R (lenzumestrocel) by the end of 2025 to gain accelerated approval from the U.S. FDA, company...
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe